CARM (CARISMA Therapeutics) General and Admin. Expense: $14.43 Mil (TTM As of Sep. 2025)


What is CARISMA Therapeutics General and Admin. Expense?

CARISMA Therapeutics CARM +1.69% General and Admin. Expense is $14.43 Mil as of Sep. 2025. The stock has 3 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. CARISMA Therapeutics's General and Admin. Expense for the three months ended in Sep. 2025 was $1.24 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2025 was $14.43 Mil.

CARISMA Therapeutics General and Admin. Expense Related Terms

CARISMA Therapeutics General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for CARISMA Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics General and Admin. Expense Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
General and Admin. Expense
5.09 6.41 9.38 29.53 22.14

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.20 5.93 3.91 3.35 1.24

CARISMA Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of $14.43 Mil mean?
CARISMA Therapeutics (CARM) has a General and Admin. Expense of $14.43 Mil as of Sep. 2025. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on CARISMA Therapeutics and its competitors.
Is CARISMA Therapeutics' General and Admin. Expense too high?
CARISMA Therapeutics' current General and Admin. Expense is $14.43 Mil.
How does CARISMA Therapeutics' General and Admin. Expense compare to SCPX and CYTOF?
CARISMA Therapeutics' General and Admin. Expense of $14.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on CARISMA Therapeutics and its competitors. CARISMA Therapeutics's current General and Admin. Expense is $14.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.01 — trading 99.8% below its estimated fair value. The current General and Admin. Expense is $14.43 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current General and Admin. Expense is $14.43 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARISMA Therapeutics Business Description

Address 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.